View Older Stories View More Recent Stories

May 11, 2017 08:13AM Novocure (NVCR) Names Martin Madden to the Board of Directors
May 11, 2017 08:12AM Martin J. Madden Joins Novocure Board of Directors
May 8, 2017 07:10AM Novocure (NVCR) Announces Results From Study of Optune Combo with Temozolomide in Newly Diagnosed Glioblastoma
May 8, 2017 07:00AM Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Several Health-Related Quality of Life Scales Compared to Temozolomide Alone for Newly Diagnosed Glioblast
May 4, 2017 07:16AM Novocure (NVCR) to Open Two Pilot Trials to Evaluate the Use of TTFields for Pediatric
May 4, 2017 07:00AM Novocure™ Announces Opening of Two Pilot Trials to Evaluate the Use of TTFields for Pediatric Gliomas
May 1, 2017 07:30AM Novocure to Present at Three Upcoming Investor Conferences in May
May 1, 2017 07:25AM Novocure™ Announces Data Presentations at the World Federation of Neuro-oncology Societies 5th Quadrennial Meeting
Apr 27, 2017 06:00AM Novocure Reports First Quarter 2017 Financial Results and Provides Company Update
Apr 19, 2017 07:00AM Novocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurology Annual Meeting in Boston
Apr 17, 2017 07:00AM CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence
Apr 3, 2017 06:21AM Novocure (NVCR) Says Combination of Optune with Standard of Care Chemotherapy Provides Landmark Five-Year Survival Rates for Newly Diagnosed GBM
Apr 2, 2017 11:00AM Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates for Newly Diagnosed Glioblastoma Patients
Mar 31, 2017 04:33PM Novocure (NVCR) Says Combination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent Ovarian Cancer
Mar 31, 2017 04:32PM Novocure (NVCR) Says Combination of Tumor Treating Fields with Standard of Care Therapies, Nab-Paclitaxel and Gemcitabine, Suggests Improved Survival of Patients with Advanced Pancreatic Cancer
Mar 31, 2017 04:30PM Combination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent Ovarian Cancer
Mar 31, 2017 04:30PM Combination of Tumor Treating Fields with Standard of Care Therapies, Nab-Paclitaxel and Gemcitabine, Suggests Improved Survival of Patients with Advanced Pancreatic Cancer
Mar 31, 2017 08:05AM Novocure Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields in Combination with Standard of Care Chemotherapy in Mesothelioma
Mar 28, 2017 07:00AM Novocure to Report First Quarter 2017 Financial Results
Mar 28, 2017 06:50AM Novocure to Present at the 16th Annual Needham & Company Healthcare Conference
Mar 20, 2017 07:14AM Novocure (NVCR) Announces Japan MHLW Approval for Second Generation of Optune
Mar 20, 2017 07:00AM Novocure Receives MHLW Approval for Second Generation Optune® in Japan
Mar 1, 2017 04:49PM Novocure (NVCR) Announces Data Presentations at AACR
Mar 1, 2017 04:49PM Novocure Announces Data Presentations at the American Association for Cancer Research Annual Meeting 2017
Feb 23, 2017 06:05AM Novocure Announces Departure of Chief Commercial Officer
Feb 23, 2017 06:00AM Novocure Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Company Update
Feb 15, 2017 07:20AM Novocure (NVCR) Says First Patient Enrolled in Phase 3 LUNAR Trial
Feb 15, 2017 07:00AM First Patient Enrolled in Novocure’s Phase 3 Pivotal LUNAR Trial Testing Tumor Treating Fields for the Treatment of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy
Feb 7, 2017 07:00AM Novocure to Participate in the BIO 2017 CEO & Investor Conference
Jan 24, 2017 07:00AM Novocure to Participate in Noble Capital Markets’ 13th Annual Investor Conference
Jan 19, 2017 07:00AM Novocure’s Optune® Now Available at 500 Cancer Treatment Centers in the U.S.
Jan 10, 2017 07:00AM Novocure Announces Preliminary Fourth Quarter and Full Year 2016 Operating Statistics
Jan 10, 2017 07:00AM Novocure to Report Fourth Quarter and Full Year 2016 Financial Results
Dec 19, 2016 07:29AM Novocure's (NVCR) Optune Approved in Japan for Glioblastoma
Dec 19, 2016 07:27AM Novocure’s Optune® (NovoTTF-100A) Approved in Japan for the Treatment of Newly Diagnosed Glioblastoma
Dec 15, 2016 07:00AM Novocure to Participate in 35th Annual J.P. Morgan Healthcare Conference
Dec 12, 2016 04:03PM Novocure (NVCR) Second Cohort Phase 2 Pilot PANOVA Trial Results Suggests Treatment Tolerable and Safe in Patients with Advanced Pancreatic Cancer
Dec 12, 2016 04:01PM Novocure (NVCR) Phase 2 Pilot INNOVATE Trial Data Suggests More than Doubling of Progression Free Survival
Dec 12, 2016 04:00PM Novocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel may be Safe as First-Line Treatment and may Improve Survival of Patients with Recurrent Ovarian
Dec 12, 2016 04:00PM Novocure Presents Second Cohort of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fields Plus Nab-Paclitaxel and Gemcitabine may be Safe as First-Line Treatment and may Improve One-Year
Dec 8, 2016 07:42AM Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016
Nov 18, 2016 07:02AM Novocure (NVCR) Announces Strong Long-Term Data from Optune Combo Phase 3 in GBM
Nov 18, 2016 07:00AM Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Fo
Nov 17, 2016 07:34AM Novocure (NVCR) Announces Presentation of Positive Interim STELLAR Trial Data in Mesothelioma
Nov 17, 2016 07:30AM Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields Plus Chemotherapy may Extend Survival of Patients with Mesothelioma
Nov 14, 2016 07:00AM Novocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology
Nov 7, 2016 07:15AM Novocure (NVCR) Will Make 38 TTFields-Focused Abstract Presentations at Annual SNO Meeting
Nov 7, 2016 07:00AM Novocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of the Society of Neuro-Oncology
Nov 3, 2016 07:00AM United Healthcare Issues Positive Coverage Decision for Optune
Nov 2, 2016 06:00AM Novocure Reports Third Quarter 2016 Financial Results and Provides Company Update
View More Recent Stories View Older Stories